A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sickness Impact Profile: Development and Final Revision of a Health Status Measure
Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S. (1981) · Medical Care · doi:10.1097/00005650-198108000-00001 · Cited by 4,619
Haverkamp, L. J., Appel, V., & Appel, S. H. (1995) · Brain · doi:10.1093/brain/118.3.707 · Cited by 696
Miller, R. G., Petajan, J. H., Bryan, W. W., Armon, C., Barohn, R. J., Goodpasture, J. C., Hoagland, R. J., Parry, G. J., Ross, M. A., Stromatt, S. C., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390215 · Cited by 345
A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience
Appel, V., Stewart, S. S., Smith, G., & Appel, S. H. (1987) · Annals of Neurology · doi:10.1002/ana.410220308 · Cited by 226
A new look and feel: Message from the Editor-in-Chief
Daroff, R. B. (1996) · Neurology · doi:10.1212/wnl.46.1.1 · Cited by 213
Changes in policy for publishing manuscripts in Neurology
Griggs, R. C. (1997) · Neurology · doi:10.1212/wnl.49.1.1 · Cited by 108
New Strategies in Oral Immunotherapy for Diabetes Prevention
MUIR, A. B., & Ramiya, V. K. (1996) · Diabetes/Metabolism Reviews · doi:10.1002/(sici)1099-0895(199603)12:1<1::aid-dmr154>3.0.co;2-g · Cited by 10
Cited by
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors
Boillée, S., Vande Velde, C., & Cleveland, D. W. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.018 · Cited by 1,429
From charcot to lou gehrig: deciphering selective motor neuron death in als
Cleveland, D. W., & Rothstein, J. D. (2001) · Nature Reviews Neuroscience · doi:10.1038/35097565 · Cited by 1,389
Prognostic factors in ALS: A critical review
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802566824 · Cited by 1,172
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
Self-citationCurrent hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703
VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection
Storkebaum, E., Lambrechts, D., & Carmeliet, P. (2004) · BioEssays · doi:10.1002/bies.20092 · Cited by 507
The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain
Russo, V. C., Gluckman, P. D., Feldman, E. L., & Werther, G. A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0024 · Cited by 492
Axonal pathology in multiple sclerosis: relationship to neurologic disability
Trapp, B. D., Ransohoff, R., & Rudick, R. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199906000-00008 · Cited by 475
ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451
“…s.c. MVIC 1; 1–2; 2–3; 3 Failure Mixed Miller et al., 1993, 1996; ALS CNTF Treatment Study Group, 1995, 1996 IGF-1 s.c. AALS; MMT 3 Failure Mixed Lai et al., 1997; Borasio et al., 1998; Sorenson et al., 2008 CSF1R inhibition Masitinib Oral ALSFRS-R 2–3 Positive$ Industry Other Lithium Oral…”
BackgroundTraynor, B. J., Codd, M. B., Corr, B., Forde, C., Frost, E., & Hardiman, O. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.8.1171 · Cited by 380
IGF-I specifically enhances axon outgrowth of corticospinal motor neurons
Özdinler, P. H., & Macklis, J. D. (2006) · Nature Neuroscience · doi:10.1038/nn1789 · Cited by 341
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
Clemmons, D. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2359 · Cited by 340
Thoenen, H., & Sendtner, M. (2002) · Nature Neuroscience · doi:10.1038/nn938 · Cited by 336
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Human conditions of insulin-like growth factor-I (IGF-I) deficiency
Puche, J. E., & Castilla-Cortázar, I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-224 · Cited by 268
Early symptom progression rate is related to ALS outcome: A prospective population-based study
Chiò, A., Mora, G., Leone, M., Mazzini, L., Cocito, D., Giordana, M. T., Bottacchi, E., & Mutani, R. (2002) · Neurology · doi:10.1212/wnl.59.1.99 · Cited by 266
GDNF Delivery Using Human Neural Progenitor Cells in a Rat Model of ALS
Klein, S. M., Behrstock, S., McHugh, J., Hoffmann, K., Wallace, K., Suzuki, M., Aebischer, P., & Svendsen, C. N. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.509 · Cited by 265
Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders
Carmeliet, P., & Storkebaum, E. (2002) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2001.0290 · Cited by 252
Diabetic neuropathy and nerve regeneration
Yasuda, H., Terada, M., Maeda, K., Kogawa, S., Sanada, M., Haneda, M., Kashiwagi, A., & Kikkawa, R. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00034-0 · Cited by 241
An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model
Selvamani, A., Sathyan, P., Miranda, R. C., & Sohrabji, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032662 · Cited by 217
“IGF-1 therapy is also tolerated well in human patients [31], however its capacity to promote tumor (including glioblastoma) growth and metastasis [32,33], necessitates closely monitoring of its usage”
BackgroundNeurotrophic and Neuroregenerative Effects of GH/IGF1
Bianchi, V., Locatelli, V., & Rizzi, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112441 · Cited by 202
“Borasio, 1998 [114] 183 51 Randomized Controlled Trial IGF-1 0.”
BackgroundMethodNeuroprotective agents for clinical trials in ALS: A systematic assessment
Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O’Neill, G., Fagan, S. C., & Cudkowicz, M. E. (2006) · Neurology · doi:10.1212/01.wnl.0000223353.34006.54 · Cited by 193
Dodge, J. C., Haidet, A. M., Yang, W., Passini, M. A., Hester, M., Clarke, J., Roskelley, E. M., Treleaven, C. M., Rizo, L., Martin, H., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.60 · Cited by 160
Neudert, C., Wasner, M., & Borasio, G. D. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00612-8 · Cited by 157
Self-citationAmyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Implications
Cozzolino, M., Ferri, A., & Teresa Carrì, M. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1760 · Cited by 156
Kaufmann, P., Levy, G., Montes, J., Buchsbaum, R., Barsdorf, A. I., Battista, V., Arbing, R., Gordon, P. H., Mitsumoto, H., Levin, B., et al. (2007) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960600888156 · Cited by 145
Quality of life and measures of quality of life in patients with neuromuscular disorders
Burns, T. M., Graham, C. D., Rose, M. R., & Simmons, Z. (2012) · Muscle & Nerve · doi:10.1002/mus.23245 · Cited by 132
Bartus, R. T., & Johnson, E. M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.03.027 · Cited by 97
Arce, V. M., Devesa, P., & Devesa, J. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.03.014 · Cited by 70
Metadata
- Authors
- Borasio, G. D., Robberecht, W., Leigh, P. N., Emile, J., Guiloff, R. J., Jerusalem, F., Silani, V., Vos, P. E., Wokke, J. H. J., Dobbins, T., & European ALS/IGF-I Study Group*
- Venue
- Neurology
- Published
- 1998-08
- Volume
- 51
- Issue
- 2
- Pages
- 583-586
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2090227048
- Cited by
- 340
- References
- 7
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.